Resilience and Frailty in People Living With HIV During the COVID Era: Two Complementary Constructs Associated With Health-Related Quality of Life.


Journal

Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005

Informations de publication

Date de publication:
01 Feb 2022
Historique:
entrez: 11 1 2022
pubmed: 12 1 2022
medline: 19 1 2022
Statut: ppublish

Résumé

Resilience is defined as an individual's positive adaptation to stressors. The COVID-19 pandemic represents a generalized stressor which may affect differently people living with HIV (PLWH). The objective of this study was to characterize resilience in PLWH with particular regarding the identification of frailty-resilience phenotypes, which may differently affect health-related quality of life (HR-QoL). This was an observational study of PLWH attending Modena HIV Metabolic Clinic. Frailty was assessed in 2019, before the onset of the COVID-19 pandemic by using 37-Item frailty index ranging from 0 to 1. The frailty index score was categorized as fit (<0.25) or frail (>0.25). In January 2021, PLWH were offered to complete a set of electronic questionnaires including the CD-RISC-25 for resilience and EQ-5D5L and SF-36 for HR-QoL. Resilience was defined as CD-RISC-25 score >75.7 (ranging from 0 to 100). Of 800 PLWH reached by mail, 575 (72%) completed the questionnaires. The median age and HIV duration were 54.5 and 24.3 years, respectively. Impaired resilience was associated with loneliness [odds ratio (OR = 2.39; 1.20 to 4.76, P < 0.001)]. Predictors for EQ-5D5L <89.7% were the phenotypes "frail/nonresilient" [OR = 5.21, 95% confidence interval (CI): 2.62 to 10.33] and "fit/nonresilient" (OR = 5.48, 95% CI: 2.8 to 10.74). Predictors for SF-36 <64.40 were the phenotypes "frail/nonresilient" (OR = 7.43, 95% CI: 2.57 to 21.22) and "fit/nonresilient" (OR = 6.27, 95% CI: 2.17 to 18.16). Both models were corrected for age, sex, HIV duration, and nadir CD4. Resilience characterizes the well-being of PLWH during the COVID-19 crisis. This construct is complementary to frailty in the identification of clinical phenotypes with different impacts on HR-QoL.

Sections du résumé

BACKGROUND BACKGROUND
Resilience is defined as an individual's positive adaptation to stressors. The COVID-19 pandemic represents a generalized stressor which may affect differently people living with HIV (PLWH). The objective of this study was to characterize resilience in PLWH with particular regarding the identification of frailty-resilience phenotypes, which may differently affect health-related quality of life (HR-QoL).
METHODS METHODS
This was an observational study of PLWH attending Modena HIV Metabolic Clinic. Frailty was assessed in 2019, before the onset of the COVID-19 pandemic by using 37-Item frailty index ranging from 0 to 1. The frailty index score was categorized as fit (<0.25) or frail (>0.25). In January 2021, PLWH were offered to complete a set of electronic questionnaires including the CD-RISC-25 for resilience and EQ-5D5L and SF-36 for HR-QoL. Resilience was defined as CD-RISC-25 score >75.7 (ranging from 0 to 100).
RESULTS RESULTS
Of 800 PLWH reached by mail, 575 (72%) completed the questionnaires. The median age and HIV duration were 54.5 and 24.3 years, respectively. Impaired resilience was associated with loneliness [odds ratio (OR = 2.39; 1.20 to 4.76, P < 0.001)]. Predictors for EQ-5D5L <89.7% were the phenotypes "frail/nonresilient" [OR = 5.21, 95% confidence interval (CI): 2.62 to 10.33] and "fit/nonresilient" (OR = 5.48, 95% CI: 2.8 to 10.74). Predictors for SF-36 <64.40 were the phenotypes "frail/nonresilient" (OR = 7.43, 95% CI: 2.57 to 21.22) and "fit/nonresilient" (OR = 6.27, 95% CI: 2.17 to 18.16). Both models were corrected for age, sex, HIV duration, and nadir CD4.
CONCLUSIONS CONCLUSIONS
Resilience characterizes the well-being of PLWH during the COVID-19 crisis. This construct is complementary to frailty in the identification of clinical phenotypes with different impacts on HR-QoL.

Identifiants

pubmed: 35015747
doi: 10.1097/QAI.0000000000002865
pii: 00126334-202202011-00010
pmc: PMC8751290
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

S65-S72

Informations de copyright

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

G.G. and C.M. received research grant and speaker honorarium from Gilead, ViiV, MERCK, and Jansen. G.G. and C.M. attended advisory boards of Gilead, ViiV, and MERCK. The other authors have no funding or conflicts of interest to disclose.

Références

CDC. Coronavirus Disease 2019 (COVID-19) in People With HIV. Centers for Disease Control and Prevention. 2020. Available at: https://www.cdc.gov/coronavirus/2019-ncov/specific-groups/hiv.html . Accessed May 1, 2021.
Capeau J. Premature aging and premature age-related comorbidities in HIV-infected patients: facts and hypotheses. Clin Infect Dis. 2011;53:1127–1129.
Brothers TD, Kirkland S, Guaraldi G, et al. Frailty in people aging with human immunodeficiency virus (HIV) infection. J Infect Dis. 2014;210:1170–1179.
Greene M, Covinsky KE, Valcour V, et al. Geriatric syndromes in older HIV-infected adults. J Acquir Immune Defic Syndr. 2015;69:161–167.
Earnshaw VA, Smith LR, Chaudoir SR, et al. HIV stigma mechanisms and well-being among PLWH: a test of the HIV stigma framework. AIDS Behav. 2013;17:1785–1795.
Lazarus JV, Safreed-Harmon K, Barton SE, et al. Beyond viral suppression of HIV—the new quality of life frontier. BMC Med. 2016;14:94.
Guaraldi G, Milic J, Martinez E, et al. HIV care models during the COVID-19 era. Clin Infect Dis. 2021;73:e1222–e1227.
Lazarus JV, Safreed-Harmon K, Kamarulzaman A, et al. Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. Nat Commun. 2021;12:4450.
Morley JE, Vellas B, Kan GA, et al. Frailty consensus: a call to action. J Am Med Dir Assoc. 2013;14:392–397.
Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet. 2013;381:752–762.
Ferrucci L, Gonzalez-Freire M, Fabbri E, et al. Measuring biological aging in humans: a quest. Aging Cell. 2020;19:e13080.
Resnick B, Galik E, Dorsey S, et al. Reliability and validity testing of the physical resilience measure. Gerontologist. 2011;51:643–652.
Whitson HE, Duan-Porter W, Schmader KE, et al. Physical resilience in older adults: systematic review and development of an emerging construct. J Gerontol A Biol Sci Med Sci. 2016;71:489–495.
Guaraldi G, Milic J. The interplay between frailty and intrinsic capacity in aging and HIV infection. AIDS Res Hum Retroviruses. 2019;35:1013–1022.
Lovibond SH, Lovibond PF. Australia PF of Manual for the Depression Anxiety Stress Scales. Sydney, Australia: Psychology Foundation of Australia; 1995.
Morin CM, Belleville G, Bélanger L, et al. The insomnia severity index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011;34:601–608.
Guaraldi G, Malagoli A, Theou O, et al. Correlates of frailty phenotype and frailty index and their associations with clinical outcomes. HIV Med Engl. 2017;18:764–771.
Guaraldi G, Brothers TD, Zona S, et al. A frailty index predicts survival and incident multimorbidity independent of markers of HIV disease severity. AIDS. 2015;29:1633–1641.
Connor K, Davidson J. Connor-Davidson resilience scale (CD-RISC) manual. CDRISC. 2003;2:76–82.
Lamond AJ, Depp CA, Allison M, et al. Measurement and predictors of resilience among community-dwelling older women. J Psychiatr Res. 2008;43:148–154.
EQ-5D-5L User Guide. Basic Information on How to Use the EQ-5D-5L Instrument. Available at: https://euroqol.org/publications/user-guides/ . Accessed April 28, 2021.
Garcia-Gordillo MA, Adsuar JC, Olivares PR. Normative values of EQ-5D-5L: in a Spanish representative population sample from Spanish Health Survey, 2011. Qual Life Res. 2016;25:1313–1321.
36-Item Short Form Survey (SF-36) Scoring Instructions. Available at: https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form/scoring.html . Accessed April 28, 2021.
Hays RD, Sherbourne CD, Mazel RM. User's Manual for the Medical Outcomes Study (MOS) Core Measures of Health-Related Quality of Life. Available at: https://www.rand.org/content/dam/rand/pubs/monograph_reports/2008/MR162.pdf . Accessed April 28, 2021.
Emlet CA, Brennan DJ, Brennenstuhl S, et al. The impact of HIV-related stigma on older and younger adults living with HIV disease: does age matter? AIDS Care. 2015;27:520–528.
Jones DL, Rodriguez VJ, Salazar AS, et al. Sex differences in the association between stress, loneliness, and COVID-19 burden among people with HIV in the United States. AIDS Res Hum Retroviruses. 2021;37:314–321.
Ye Z, Sun L, Wang Q. A head-to-head comparison of EQ-5D-5 L and SF-6D in Chinese patients with low back pain. Health Qual Life Outcomes. 2019;17:57.
Zhao L, Liu X, Liu D, et al. Comparison of the psychometric properties of the EQ-5D-3L and SF-6D in the general population of Chengdu city in China. Medicine (Baltimore). 2019;98:e14719.
Kularatna S, Senanayake S, Gunawardena N, et al. Comparison of the EQ-5D 3L and the SF-6D (SF-36) contemporaneous utility scores in patients with chronic kidney disease in Sri Lanka: a cross-sectional survey. BMJ Open. 2019;9:1–9.
Francesco DD, Wit FW, Bürkle A, et al. Do people living with HIV experience greater age advancement than their HIV-negative counterparts? AIDS. 2019;33:259–268.
Karpiak SE, Havlik R. Are HIV-infected older adults aging differently? Interdiscip Top Gerontol Geriatr. 2016;42:11–27.
Pathai S, Bajillan H, Landay AL, et al. Is HIV a model of accelerated or accentuated aging? J Gerontol A Biol Sci Med Sci. 2014;69:833–842.

Auteurs

Giovanni Guaraldi (G)

Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Modena HIV Metabolic Clinic (MHMC), University of Modena and Reggio Emilia, Modena, Italy.
Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy; and.

Jovana Milic (J)

Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Modena HIV Metabolic Clinic (MHMC), University of Modena and Reggio Emilia, Modena, Italy.

Sara Barbieri (S)

Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy.

Tommaso Marchiò (T)

University of Modena and Reggio Emilia, Modena, Italy.

Agnese Caselgrandi (A)

University of Modena and Reggio Emilia, Modena, Italy.

Sara Volpi (S)

Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy; and.

Emanuele Aprile (E)

Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy; and.

Michela Belli (M)

Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy; and.

Maria Venuta (M)

Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy; and.

Cristina Mussini (C)

Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy; and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH